{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:15:38Z","timestamp":1768295738654,"version":"3.49.0"},"reference-count":195,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.autrev.2015.08.011","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T22:39:41Z","timestamp":1440801581000},"page":"50-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Delineating the deranged immune system in the antiphospholipid syndrome"],"prefix":"10.1016","volume":"15","author":[{"given":"Lucas L.","family":"van den Hoogen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00ebl A.G.","family":"van Roon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.D.J.","family":"Radstake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth D.E.","family":"Fritsch-Stork","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald H.W.M.","family":"Derksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2015.08.011_bb0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.autrev.2015.01.002","article-title":"The relevance of \u201cnon-criteria\u201d clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features","volume":"14","author":"Abreu","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.autrev.2014.11.003","article-title":"Antiphospholipid syndrome and the heart: a case series and literature review","volume":"14","author":"Denas","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0020","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.autrev.2014.05.001","article-title":"14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends","volume":"13","author":"Bertolaccini","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.autrev.2013.10.004","article-title":"Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the \u201cCAPS registry\u201d","volume":"13","author":"Berman","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.autrev.2014.03.002","article-title":"14Th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome","volume":"13","author":"Cervera","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.clim.2004.02.012","article-title":"B2-Glycoprotein I, the playmaker of the antiphospholipid syndrome","volume":"112","author":"De Laat","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0040","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2009-12-260976","article-title":"\u03b22-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome","volume":"116","author":"A\u01e7ar","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0045","first-page":"1916","article-title":"Pathogenic anti \u2013 beta 2 -glycoprotein I antibodies recognize domain I of beta 2 -glycoprotein I only after a conformational change","volume":"107","author":"De Laat","year":"2006","journal-title":"Hemost Thromb Vasc Biol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0050","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2004-03-1107","article-title":"B2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome","volume":"104","author":"De Laat","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1160\/TH06-05-0287","article-title":"Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity","volume":"96","author":"Ruffatti","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0060","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0065","first-page":"2214","article-title":"Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis","volume":"33","author":"Opatrny","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0070","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0080","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0085","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.autrev.2014.12.010","article-title":"The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases","volume":"14","author":"Alijotas-Reig","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0090","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0095","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1182\/blood-2010-08-300715","article-title":"\u03b22-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model","volume":"117","author":"Arad","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0100","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/rheumatology\/keu360","article-title":"Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of 2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis","volume":"54","author":"Pericleous","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2015.08.011_bb0105","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2015.08.011_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-014-0485-9","article-title":"The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome","volume":"17","author":"Willis","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2015.08.011_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2015.01.008","article-title":"Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature","volume":"14","author":"Viall","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/humupd\/dmu049","article-title":"Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment","volume":"21","author":"Tong","year":"2014","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.autrev.2015.08.011_bb0125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2141.1980.tb03814.x","article-title":"Familial association of the lupus anticoagulant","volume":"45","author":"Exner","year":"1980","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jcp.42.5.495","article-title":"Familial occurrence of the antiphospholipid syndrome","volume":"42","author":"Matthey","year":"1989","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0135","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1161\/01.STR.21.1.66","article-title":"Premature stroke in a family with lupus anticoagulant and antiphospholipid antibodies","volume":"21","author":"Ford","year":"1990","journal-title":"Stroke"},{"key":"10.1016\/j.autrev.2015.08.011_bb0140","series-title":"Antiphospholipid antibody syndrome from bench to bedside","first-page":"1","article-title":"Genetics and origin of antiphospholipid syndrome","author":"Soriano","year":"2015"},{"key":"10.1016\/j.autrev.2015.08.011_bb0145","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1182\/blood-2014-08-593624","article-title":"\u03b22-Glycoprotein I\/HLA class II complexes are novel autoantigens in antiphospholipid syndrome","volume":"125","author":"Tanimura","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1568-9972(03)00068-5","article-title":"HLA class II alleles and genetic predisposition to the antiphospholipid syndrome","volume":"2","author":"Domenico Sebastiani","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0155","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1002\/art.24701","article-title":"Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome","volume":"60","author":"Yin","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0160","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/art.27345","article-title":"IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor","volume":"62","author":"Fredi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0165","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/ard.2008.094367","article-title":"STAT4 single nucleotide polymorphism, rs7574865 G\/T, as a risk for antiphospholipid syndrome","volume":"68","author":"Horita","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0170","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1086\/428480","article-title":"Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus","volume":"76","author":"Sigurdsson","year":"2005","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.autrev.2015.08.011_bb0175","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa073003","article-title":"STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus","volume":"357","author":"Remmers","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.08.011_bb0180","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJMoa0707865","article-title":"Association of systemic lupus erythematosus with C8orf13\u2013BLK and ITGAM\u2013ITGAX","volume":"358","author":"Hom","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.08.011_bb0185","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.autrev.2011.12.006","article-title":"Val247Leu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: systematic review and meta-analysis","volume":"11","author":"Chamorro","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0190","article-title":"Genome-wide association study of antiphospholipid antibodies","volume":"2013","author":"Kamboh","year":"2013","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0195","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/ard.2006.065037","article-title":"Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies","volume":"66","author":"Pierangeli","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0200","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1055\/s-0037-1615095","article-title":"Fcgamma receptor IIA H\/R131 polymorphism in patients with antiphospholipid antibodies","volume":"79","author":"Atsumi","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0205","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/art.11059","article-title":"Role of the Fc\u03b3 receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis","volume":"48","author":"Karassa","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0210","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0961203313490242","article-title":"The involvement of CD36 in monocyte activation by antiphospholipid antibodies","volume":"22","author":"Kato","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2015.08.011_bb0215","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1055\/s-0037-1615676","article-title":"Plasma tumor necrosis factor alpha levels and the \u2212238*A promoter polymorphism in patients with antiphospholipid syndrome","volume":"85","author":"Bertolaccini","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0220","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.thromres.2014.12.004","article-title":"Annexin A5 haplotypes in the antiphospholipid syndrome","volume":"135","author":"Hiddink","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2015.08.011_bb0225","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1136\/ard.2005.045237","article-title":"Annexin A5 polymorphism (-1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome","volume":"65","author":"De Laat","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0230","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.thromres.2011.10.005","article-title":"The impact of platelet membrane glycoprotein Ib alpha and Ia\/IIa polymorphisms on the risk of thrombosis in the antiphospholipid syndrome","volume":"129","author":"Yonal","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2015.08.011_bb0235","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/ard.2007.077321","article-title":"Double heterozygosity polymorphisms for platelet glycoproteins Ia\/IIa and IIb\/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus","volume":"67","author":"Jim\u00e9nez","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0240","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1136\/ard.2007.075945","article-title":"P-selectin glycoprotein ligand-1 VNTR polymorphisms and risk of thrombosis in the antiphospholipid syndrome","volume":"66","author":"Diz-Kucukkaya","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0245","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2141.2009.07831.x","article-title":"Genetic risk factors of thrombosis in the antiphospholipid syndrome","volume":"147","author":"Castro-Marrero","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0250","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/annrheumdis-2013-205159","article-title":"Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus","volume":"74","author":"Gustafsson","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0255","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.10130","article-title":"Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo","volume":"46","author":"Gharavi","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0260","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1172\/JCI0212337","article-title":"Bacterial induction of autoantibodies to B2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome","volume":"109","author":"Blank","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2015.08.011_bb0265","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1111\/j.1538-7836.2011.04532.x","article-title":"Induction of anti-\u03b2 2-glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes","volume":"9","author":"Van Os","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0270","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.4049\/jimmunol.165.11.6037","article-title":"BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood","volume":"165","author":"Dzionek","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0275","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.immuni.2011.05.013","article-title":"The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity","volume":"35","author":"Kool","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2015.08.011_bb0280","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/08916930701356572","article-title":"Requirement for dendritic cells in the establishment of anti-phospholipid antibodies","volume":"40","author":"Bondanza","year":"2007","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2015.08.011_bb0285","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/art.20187","article-title":"Requirement of dying cells and environmental adjuvants for the induction of autoimmunity","volume":"50","author":"Bondanza","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0290","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2004-08-3145","article-title":"Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells","volume":"105","author":"Kuwana","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0295","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1182\/blood-2007-07-100008","article-title":"Excessive exposure to anionic surfaces maintains autoantibody response to beta(2)-glycoprotein I in patients with antiphospholipid syndrome","volume":"110","author":"Yamaguchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0300","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/1529-0131(199907)42:7<1412::AID-ANR15>3.0.CO;2-T","article-title":"Dendritic cell presentation of antigens from apoptotic cells in a proinflammatory context: role of opsonizing anti-2-glycoprotein I antibodies","volume":"42","author":"Rovere","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0305","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1006\/jaut.1998.0224","article-title":"Dendritic cells preferentially internalize apoptotic cells opsonized by anti-2-glycoprotein I antibodies","volume":"11","author":"Rovere","year":"1998","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2015.08.011_bb0310","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.08.011_bb0315","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.4049\/jimmunol.177.9.6504","article-title":"Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus","volume":"177","author":"Levine","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0320","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/0961203314534308","article-title":"Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality","volume":"23","author":"Ara","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2015.08.011_bb0325","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0961203309360541","article-title":"Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort","volume":"19","author":"Petri","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2015.08.011_bb0330","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1002\/art.30383","article-title":"Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen \u03b22-glycoprotein I","volume":"63","author":"Ioannou","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0335","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2005-03-1201","article-title":"Oxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response","volume":"106","author":"Buttari","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0340","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/annrheumdis-2011-200063","article-title":"Tolerogenic dendritic cells inhibit antiphospholipid syndrome derived effector\/memory CD4+ T cell response to \u03b22GPI","volume":"71","author":"Torres-Aguilar","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0345","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nri3865","article-title":"The multifaceted biology of plasmacytoid dendritic cells","volume":"15","author":"Swiecki","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0350","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nri2358","article-title":"Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases","volume":"8","author":"Gilliet","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0355","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2015.08.011_bb0360","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2015.08.011_bb0365","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0370","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/art.37821","article-title":"Disease mechanisms in rheumatology--tools and pathways: plasmacytoid dendritic cells and their role in autoimmune rheumatic diseases","volume":"65","author":"Eloranta","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0375","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.gene.6364443","article-title":"Innate immune response gene expression profiles characterize primary antiphospholipid syndrome","volume":"9","author":"Bernales","year":"2008","journal-title":"Genes Immun"},{"issue":"7","key":"10.1016\/j.autrev.2015.08.011_bb0380","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/annrheumdis-2013-204600","article-title":"Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus","volume":"74","author":"Perez-Sanchez","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0385","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0390","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood-2011-01-330639","article-title":"Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells","volume":"118","author":"Prinz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0395","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.imbio.2008.12.003","article-title":"TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells","volume":"214","author":"Hurst","year":"2009","journal-title":"Immunobiology"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2015.08.011_bb0400","article-title":"Involvement of TLR7 and TLR9 in the production of antiphospholipid antibodies","volume":"63","author":"Aguilar-Valenzuela","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0405","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/1097-0142(19940315)73:6<1621::AID-CNCR2820730613>3.0.CO;2-E","article-title":"Antiphospholipid syndrome associated with immunotherapy for patients with melanoma","volume":"73","author":"Becker","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.autrev.2015.08.011_bb0410","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Stavropoulou-giokas","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.08.011_bb0415","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Kuznik","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0420","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrrheum.2012.106","article-title":"New insights into mechanisms of therapeutic effects of antimalarial agents in SLE","volume":"8","author":"Wallace","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0425","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/ar3895","article-title":"Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"14","author":"Sacre","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2015.08.011_bb0430","first-page":"6","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0435","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.autrev.2015.04.010","article-title":"Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?","volume":"14","author":"De Carolis","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0440","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Anti-thrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"Schmidt-Tanguy","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0445","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.autrev.2014.12.006","article-title":"Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome","volume":"14","author":"Belizna","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0450","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.autrev.2012.12.006","article-title":"Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies","volume":"12","author":"Comarmond","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0455","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1568-9972(03)00007-7","article-title":"Autoreactive CD4 T cells to b 2-glycoprotein I in patients with antiphospholipid syndrome","volume":"2","author":"Kuwana","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0460","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.thromres.2004.06.029","article-title":"Beta2-glycoprotein I: antiphospholipid syndrome and T-cell reactivity","volume":"114","author":"Kuwana","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2015.08.011_bb0465","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/1529-0131(200001)43:1<65::AID-ANR9>3.0.CO;2-I","article-title":"T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals","volume":"43","author":"Hattori","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0470","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood.V98.6.1889","article-title":"Autoreactive CD4+ T-cell clones to beta2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site","volume":"98","author":"Arai","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0475","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.V99.7.2499","article-title":"Restricted T-cell receptor beta-chain usage by T cells autoreactive to beta 2-glycoprotein I in patients with antiphospholipid syndrome","volume":"99","author":"Yoshida","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0480","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.4049\/jimmunol.162.11.6919","article-title":"Cellular immunity to beta 2-glycoprotein-1 in patients with the antiphospholipid syndrome","volume":"162","author":"Visvanathan","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0485","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/rheumatology\/41.4.395","article-title":"Immune responses to native beta(2)-glycoprotein I in patients with systemic lupus erythematosus and the antiphospholipid syndrome","volume":"41","author":"Davies","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.08.011_bb0490","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1161\/ATVBAHA.113.302680","article-title":"Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on \u03b22GPI-specific T cell response","volume":"34","author":"Conti","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0495","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.autrev.2014.10.012","article-title":"Regulatory T-cells in autoimmune diseases: challenges, controversies and\u2014yet\u2014unanswered questions","volume":"14","author":"Grant","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0500","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.autrev.2014.08.019","article-title":"Th17 cells in inflammation and autoimmunity","volume":"13","author":"Singh","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0505","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0510","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00277-004-0910-7","article-title":"Type 1 and type 2 cytokine-producing CD4+ and CD8+ T cells in primary antiphospholipid syndrome","volume":"83","author":"Karakantza","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0515","first-page":"2242","article-title":"T lymphocyte subsets in primary antiphospholipid syndrome","volume":"21","author":"Papo","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0520","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1191\/0961203305lu2181oa","article-title":"Lymphocyte subpopulations and intima media thickness in primary antiphospholipd syndrome","volume":"14","author":"Ames","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2015.08.011_bb0525","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3899\/jrheum.081079","article-title":"Quantitative abnormalities of peripheral blood distinct T, B, and natural killer cell subsets and clinical findings in obstetric antiphospholipid syndrome","volume":"36","author":"Carbone","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0530","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0198-8859(99)00184-6","article-title":"Analysis of T cell responses to the beta 2-glycoprotein I-derived peptide library in patients with anti-beta 2-glycoprotein I antibody-associated autoimmunity","volume":"61","author":"Ito","year":"2000","journal-title":"Hum Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0535","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1055\/s-0037-1616157","article-title":"Imbalance towards Th2-type response in patients with definite primary antiphospholipid syndrome","volume":"453","author":"Forestiero","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0540","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/rheumatology\/ken349","article-title":"Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction","volume":"47","author":"Soltesz","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.08.011_bb0545","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.imbio.2012.03.002","article-title":"Increased activity of interleukin-23\/interleukin-17 cytokine axis in primary antiphospholipid syndrome","volume":"218","author":"Popovic-Kuzmanovic","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.autrev.2015.08.011_bb0550","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3892\/mmr.2012.1055","article-title":"Th1\/Th2\/Th17\/Treg expression in cultured PBMCs with antiphospholipid antibodies","volume":"6","author":"Xiao","year":"2012","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.autrev.2015.08.011_bb0555","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s10875-012-9857-y","article-title":"Decreased levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome","volume":"33","author":"Dal Ben","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0560","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/annrheumdis-2014-eular.4485","article-title":"THU0504 regulatory T cells in peripheral blood of patients with antiphospholipid syndrome","volume":"73","author":"Soroka","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0565","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.autrev.2013.08.004","article-title":"The antiphospholipid syndrome and Tregs","volume":"13","author":"Staub","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0570","first-page":"241","article-title":"Patients with systemic lupus erythematosus and secondary antiphospholipid syndrome have decreased numbers of circulating CD4+CD25+Foxp3+ Treg and CD3\u2013 CD19+ B cells","volume":"54","author":"Dal Ben","year":"2014","journal-title":"Rev Bras Reumatol (English Ed)"},{"key":"10.1016\/j.autrev.2015.08.011_bb0575","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clim.2015.03.024","article-title":"Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome","volume":"158","author":"Lai","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0580","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/01443610120087805","article-title":"Lymphocyte subpopulation frequency and presence of anti-cardiolipin and anti-nuclear antibodies in peripheral blood of Kuwaiti women experiencing recurrent pregnancy loss","volume":"21","author":"Mahmoud","year":"2001","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0585","first-page":"501","article-title":"Some patients with primary antiphospholipid syndrome have increased circulating CD5+ B cells that correlate with levels of IgM antiphospholipid antibodies","volume":"9","author":"Velasquillo","year":"1991","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2015.08.011_bb0590","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/annrheumdis-2015-eular.5554","article-title":"Among patients with venous thrombo-embolism, B cell subset disturbances characterise those with primary antiphospholipid syndrome","volume":"74","author":"Simonin","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0595","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/RHU.0b013e31819c3a49","article-title":"Basic science for the clinician 49","volume":"15","author":"Sigal","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0600","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1182\/blood-2003-01-0180","article-title":"Memory B cells producing somatically mutated antiphospholipid antibodies are present in healthy individuals","volume":"102","author":"Lieby","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0605","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.23764","article-title":"Prevention of murine antiphospholipid syndrome by BAFF blockade","volume":"58","author":"Kahn","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0610","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0615","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0620","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/art.21549","article-title":"Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB\/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1\/ERK","volume":"54","author":"L\u00f3pez-Pedrera","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0625","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1002\/art.22802","article-title":"Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts","volume":"56","author":"Sorice","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0630","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.4049\/jimmunol.0902765","article-title":"Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways","volume":"184","author":"Lambrianides","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0635","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.molimm.2012.08.012","article-title":"Anti-\u03b2(2)GPI\/\u03b2(2)GPI induced TF and TNF-\u03b1 expression in monocytes involving both TLR4\/MyD88 and TLR4\/TRIF signaling pathways","volume":"53","author":"Xie","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0640","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2011-09-378851","article-title":"Autoantibodies specific to a peptide of \u03b22-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes","volume":"120","author":"Colasanti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0645","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/cr.2007.33","article-title":"Involvement of annexin A2 in anti-beta2GPI\/beta2GPI-induced tissue factor expression on monocytes","volume":"17","author":"Zhou","year":"2007","journal-title":"Cell Res"},{"key":"10.1016\/j.autrev.2015.08.011_bb0650","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1002\/art.23756","article-title":"Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis","volume":"58","author":"L\u00f3pez-Pedrera","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0655","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1182\/blood-2010-11-316158","article-title":"Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies","volume":"117","author":"Satta","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0660","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jth.12536","article-title":"NF-\u03baB is activated from endosomal compartments in antiphospholipid antibodies-treated human monocytes","volume":"12","author":"Brandt","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0665","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.imbio.2009.03.002","article-title":"Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8","volume":"215","author":"D\u00f6ring","year":"2010","journal-title":"Immunobiology"},{"key":"10.1016\/j.autrev.2015.08.011_bb0670","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.4049\/jimmunol.153.3.1328","article-title":"Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies","volume":"153","author":"Kornberg","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0675","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/art.1780400509","article-title":"Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression","volume":"40","author":"Cuadrado","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0680","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/1529-0131(199808)41:8<1420::AID-ART11>3.0.CO;2-U","article-title":"Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes","volume":"41","author":"Reverter","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0685","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1055\/s-0037-1614881","article-title":"Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome","volume":"82","author":"Dobado-Berrios","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0690","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1182\/blood-2004-01-0145","article-title":"Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep","volume":"104","author":"Zhou","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0695","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1538-7836.2006.02193.x","article-title":"Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome","volume":"4","author":"Cuadrado","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0700","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/art.27299","article-title":"Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome","volume":"62","author":"L\u00f3pez-Pedrera","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0705","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1160\/TH12-09-0655","article-title":"Both NF-\u03baB and c-Jun\/AP-1 involved in anti-\u03b22GPI\/\u03b22GPI-induced tissue factor expression in monocytes","volume":"109","author":"Xia","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0710","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/0891693031000079257","article-title":"Significance of anti-oxidized LDL antibody and monocyte-derived microparticles in anti-phospholipid antibody syndrome","volume":"36","author":"Nagahama","year":"2003","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2015.08.011_bb0715","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/0961203312437809","article-title":"Studies of microparticles in patients with the antiphospholipid syndrome (APS)","volume":"21","author":"Vikerfors","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2015.08.011_bb0720","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2014.11.011","article-title":"Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations","volume":"135","author":"Chaturvedi","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2015.08.011_bb0725","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1182\/blood-2011-12-400986","article-title":"Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment","volume":"119","author":"Perez-Sanchez","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0730","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/intimm\/dxh166","article-title":"The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies","volume":"16","author":"Bohgaki","year":"2004","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0735","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1749-6632.2009.04648.x","article-title":"Possible involvement of chemokine-induced platelet activation in thrombophilic diathesis of antiphospholipid syndrome","volume":"1173","author":"Kubota","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2015.08.011_bb0740","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1055\/s-0037-1615376","article-title":"Antiphospholipid syndrome patients' monocytes are \u201cprimed \u201d to express tissue factor","volume":"80","author":"Williams","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0745","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1538-7836.2003.00108.x","article-title":"Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment","volume":"1","author":"Ferro","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0750","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2011.04451.x","article-title":"Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome","volume":"9","author":"Teruel","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0755","doi-asserted-by":"crossref","first-page":"292851","DOI":"10.1155\/2015\/292851","article-title":"Differential regulation of proinflammatory mediators following LPS- and ATP-induced activation of monocytes from patients with antiphospholipid syndrome","volume":"2015","author":"Martirosyan","year":"2015","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.autrev.2015.08.011_bb0760","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1160\/TH14-07-0628","article-title":"Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome","volume":"113","author":"M\u00fcller-calleja","year":"2015","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.autrev.2015.08.011_bb0765","article-title":"Beneficial effects of in vivo ubiquinol supplementation on ethero-thrombosis prevention in antiphospholipid syndrome patients","volume":"66","author":"Lopez-Pedrera","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2015.08.011_bb0770","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0775","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/ard.2010.135525","article-title":"Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome","volume":"70","author":"L\u00f3pez-Pedrera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0780","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(14)60417-7","article-title":"Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial","volume":"384","author":"Newby","year":"2014","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2015.08.011_bb0785","article-title":"Characterization of micrornas involved in the regulation of atherotrhombosis in antiphospholipid syndrome and systemic lupus erythematosus","volume":"73","author":"Perez-Sanchez","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0790","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jlb.57.3.387","article-title":"Neutrophil antibodies activation by anti-B2 glycoprotein I monoclonal antibodies via Fcg receptor II","volume":"57","author":"Arvieux","year":"1995","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0795","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042176","article-title":"A role for Toll-like receptor mediated signals in neutrophils in the pathogenesis of the anti-phospholipid syndrome","volume":"7","author":"Gladigau","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2015.08.011_bb0800","first-page":"3453","article-title":"Neutrophil activation by the tissue factor \/ Factor VIIa \/ PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome","volume":"118","author":"Redecha","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2015.08.011_bb0805","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0810","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2007-01-070631","article-title":"Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody\u2212induced fetal injury Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody\u2013induced fetal injury","volume":"110","author":"Redecha","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0815","doi-asserted-by":"crossref","first-page":"73ra19","DOI":"10.1126\/scitranslmed.3001180","article-title":"Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus","volume":"3","author":"Lande","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2015.08.011_bb0820","doi-asserted-by":"crossref","first-page":"73ra20","DOI":"10.1126\/scitranslmed.3001201","article-title":"Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus","volume":"3","author":"Garcia-Romo","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2015.08.011_bb0825","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4049\/jimmunol.1100450","article-title":"Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus","volume":"187","author":"Villanueva","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0830","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078459","article-title":"Ligation of signal inhibitory receptor on leukocytes-1 suppresses the release of neutrophil extracellular traps in systemic lupus erythematosus","volume":"8","author":"Van Avondt","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2015.08.011_bb0835","doi-asserted-by":"crossref","DOI":"10.1002\/art.39247","article-title":"Antiphospholipid antibodies promote the release of neutrophil extracellular traps: a new mechanism of thrombosis in the antiphospholipid syndrome","author":"Yalavarthi","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2015.08.011_bb0840","first-page":"66","article-title":"Degradation of neutrophil extracellular traps is decreased in patients with antiphospholipid syndrome","volume":"32","author":"Leffler","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0845","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2015.08.011_bb0850","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.humimm.2005.11.003","article-title":"Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia","volume":"66","author":"Gupta","year":"2005","journal-title":"Hum Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0855","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nri3065","article-title":"Organ-specific features of natural killer cells","volume":"11","author":"Shi","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0860","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nri1897","article-title":"Immunology of placentation in eutherian mammals","volume":"6","author":"Moffett","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0865","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/humrep\/dep349","article-title":"Detailed analysis of peripheral blood natural killer (NK) cells in women with recurrent miscarriage","volume":"25","author":"King","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.autrev.2015.08.011_bb0870","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1093\/rheumatology\/kem197","article-title":"High levels of NK cells in the peripheral blood of patients affected with anti-phospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis","volume":"46","author":"Perricone","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.08.011_bb0875","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0897.1995.tb00924.x","article-title":"Up-regulated expression of CD56+, CD56+\/CD16+, and CD19+ cells in peripheral blood lymphocytes in pregnant women with recurrent pregnancy losses","volume":"34","author":"Kwak","year":"1995","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0880","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1055\/s-0029-1145261","article-title":"Pregnancy outcome in women with antiphospholipid antibodies: report on a retrospective study","volume":"34","author":"Heilmann","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0885","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jri.2012.04.003","article-title":"The correlation of autoantibodies and uNK cells in women with reproductive failure","volume":"95","author":"Mariee","year":"2012","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0890","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0895","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2011-02-339564","article-title":"\u03b22-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator","volume":"118","author":"Gropp","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0900","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2008.090670","article-title":"Complement activation in patients with primary antiphospholipid syndrome","volume":"68","author":"Oku","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.08.011_bb0905","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1160\/TH10-06-0410","article-title":"Is there an association between complement activation and antiphospholipid antibody-related thrombosis?","volume":"104","author":"Devreese","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0910","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1160\/TH11-08-0554","article-title":"Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome","volume":"107","author":"Breen","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2015.08.011_bb0915","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/rheumatology\/kes225","article-title":"Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?","volume":"51","author":"Reggia","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.08.011_bb0920","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/0961203312444172","article-title":"Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome","volume":"21","author":"De Carolis","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2015.08.011_bb0925","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2015.08.011_bb0930","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2005-03-1319","article-title":"Thrombus formation induced by antibodies to \u03b22-glycoprotein I is complement dependent and requires a priming factor","volume":"106","author":"Fischetti","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.08.011_bb0935","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody\u2013induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2015.08.011_bb0940","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends","volume":"13","author":"Erkan","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0945","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.autrev.2015.05.008","article-title":"Epigenetics in autoimmune diseases: pathogenesis and prospects for therapy","volume":"14","author":"Zhang","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.08.011_bb0950","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrrheum.2014.128","article-title":"The role of genetics and epigenetics in the pathogenesis of systemic sclerosis","volume":"10","author":"Broen","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0955","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.semarthrit.2011.09.004","article-title":"Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review","volume":"41","author":"Poulton","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.08.011_bb0960","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.thromres.2013.07.023","article-title":"From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: Pathogenic mechanisms of the antiphospholipid syndrome","volume":"132","author":"Du","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2015.08.011_bb0965","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.thromres.2013.08.015","article-title":"Receptors involved in cell activation by antiphospholipid antibodies","volume":"132","author":"Brandt","year":"2013","journal-title":"Thromb Res"},{"issue":"9","key":"10.1016\/j.autrev.2015.08.011_bb0970","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrrheum.2015.71","article-title":"Immune cell profiling to guide therapeutic decisions in rheumatic diseases","volume":"11","author":"Ermann","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2015.08.011_bb0975","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","article-title":"Precision medicine \u2014 personalized, problematic, and promising","volume":"372","author":"Jameson","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899721500186X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899721500186X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:11:04Z","timestamp":1748592664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899721500186X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":195,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S156899721500186X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2015.08.011","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delineating the deranged immune system in the antiphospholipid syndrome","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2015.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}